Sign In
to Vote &
Create Storyboards.
 
Theshold Pharmaceutical's stock plunges on heavy volume to an seven-year low after two late-stage trials of its cancer treatment failed to meet their primary endpoint.
5
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard